The Netherlands
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Qiagen scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. Qiagen By complying with the HRC’s controversial demands, Qiagen increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Qiagen forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Qiagen integrates ESG into all of its business practices and its CEO signed the CEO Action for Diversity & Inclusion pledge. However, it does not discriminate against charitable organizations based on views or beliefs. For these reasons, Qiagen receives a High Risk rating.

Generate Reports